Emtricitabine/Tenofovir Alafenamide Fumarate/Cobicistat/Elvitegravir

恩曲他滨/富马酸磷丙替诺福韦/考比司他/埃替格韦

Report date: 2026/03/18 10:10:25

Base Information

Drug NameEmtricitabine/Tenofovir Alafenamide Fumarate/Cobicistat/Elvitegravir
Drug Alias Name艾考恩丙替Elvitegravir - cobicistat - emtricitabine - tenofovir alafenamideElvitegravir/cobicistat/emtricitabine/tenofovir alafenamideelvitegravir, cobicistat, tenofovir alafenamide and emtricitabineelvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionCytochrome P450 3A inhibitorsReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitors +[4] 
TargetsCytochrome P450 3AHuman immunodeficiency virus type 1 reverse transcriptaseHIV integrase +[4] 
Therapy Area/IndicationsHepatitis BAcquired Immunodeficiency SyndromeHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2015/11/05
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsYes EmtricitabineTenofovir Alafenamide FumarateCobicistat
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesPenta Global FoundationGilead Sciences IncGilead Sciences Ireland Uc +[6] 
Inactive CompaniesEmory University
Active IndicationsHIV Infections
Inactive IndicationsHepatitis BAcquired Immunodeficiency Syndrome

Other Information

ATC CodeJ05AR18
Related LinksKEGG